German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assay

Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftaz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Manzke, Jana (VerfasserIn) , Stauf, Raphael (VerfasserIn) , Neumann, Bernd (VerfasserIn) , Molitor, Ernst (VerfasserIn) , Hischebeth, Gunnar (VerfasserIn) , Simon, Michaela (VerfasserIn) , Jantsch, Jonathan (VerfasserIn) , Rödel, Jürgen (VerfasserIn) , Becker, Sören Leif (VerfasserIn) , Halfmann, Alexander (VerfasserIn) , Wichelhaus, Thomas A. (VerfasserIn) , Hogardt, Michael (VerfasserIn) , Serr, Annerose (VerfasserIn) , Hess, Christina (VerfasserIn) , Wendel, Andreas Friedrich (VerfasserIn) , Siegel, Ekkehard (VerfasserIn) , Rohde, Holger (VerfasserIn) , Zimmermann, Stefan (VerfasserIn) , Steinmann, Jörg Helmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 April 2022
In: Antibiotics
Year: 2022, Jahrgang: 11, Heft: 5, Pages: 1-6
ISSN:2079-6382
DOI:10.3390/antibiotics11050545
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/antibiotics11050545
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2079-6382/11/5/545
Volltext
Verfasserangaben:Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann and Jörg Steinmann

MARC

LEADER 00000caa a2200000 c 4500
001 1811789064
003 DE-627
005 20250109052704.0
007 cr uuu---uuuuu
008 220727s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/antibiotics11050545  |2 doi 
035 |a (DE-627)1811789064 
035 |a (DE-599)KXP1811789064 
035 |a (OCoLC)1341464363 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Manzke, Jana  |e VerfasserIn  |0 (DE-588)1263673147  |0 (DE-627)1811789935  |4 aut 
245 1 0 |a German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assay  |c Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann and Jörg Steinmann 
264 1 |c 19 April 2022 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a This article belongs to the special issue "Carbapenem-Resistant Organisms (CRO) as leading cause of hospital associated infections" 
500 |a Gesehen am 27.07.2022 
520 |a Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for carbapenemase production and susceptibility against ceftazidime-avibactam. Meropenem-resistant isolates of P. aeruginosa from various clinical materials were collected at 11 tertiary care hospitals in Germany from 2017-2019. Minimum inhibitory concentrations (MICs) were determined via microdilution plates (MICRONAUT-S) of ceftazidime-avibactam and meropenem at each center. Detection of the presence of carbapenemases was performed by PCR or immunochromatography. For meropenem-resistant isolates (n = 448), the MIC range of ceftazidime-avibactam was 0.25-128 mg/L, MIC90 was 128 mg/L and MIC50 was 16 mg/L. According to EUCAST clinical breakpoints, 213 of all meropenem-resistant P. aeruginosa isolates were categorized as susceptible (47.5%) to ceftazidime-avibactam. Metallo-β-lactamases (MBL) could be detected in 122 isolates (27.3%). The MIC range of ceftazidime-avibactam in MBL-positive isolates was 4-128 mg/L, MIC90 was >128 mg/L and MIC50 was 32 mg/L. There was strong variation in the prevalence of MBL-positive isolates among centers. Our in vitro results support ceftazidime-avibactam as a treatment option against infections caused by meropenem-resistant, MBL-negative P. aeruginosa. 
650 4 |a carbapenemases 
650 4 |a ceftazidime-avibactam 
650 4 |a susceptibility testing 
700 1 |8 1\p  |a Stauf, Raphael  |d 1990-  |e VerfasserIn  |0 (DE-588)1236404556  |0 (DE-627)1761762133  |4 aut 
700 1 |a Neumann, Bernd  |e VerfasserIn  |4 aut 
700 1 |a Molitor, Ernst  |e VerfasserIn  |4 aut 
700 1 |a Hischebeth, Gunnar  |e VerfasserIn  |4 aut 
700 1 |8 2\p  |a Simon, Michaela  |e VerfasserIn  |0 (DE-588)139683070  |0 (DE-627)612701425  |0 (DE-576)312729219  |4 aut 
700 1 |a Jantsch, Jonathan  |e VerfasserIn  |4 aut 
700 1 |8 3\p  |a Rödel, Jürgen  |d 1958-  |e VerfasserIn  |0 (DE-588)1027556329  |0 (DE-627)729360369  |0 (DE-576)373346522  |4 aut 
700 1 |8 4\p  |a Becker, Sören Leif  |d 1985-  |e VerfasserIn  |0 (DE-588)1018124713  |0 (DE-627)680395806  |0 (DE-576)354407759  |4 aut 
700 1 |8 5\p  |a Halfmann, Alexander  |d 1979-  |e VerfasserIn  |0 (DE-588)135620694  |0 (DE-627)568602420  |0 (DE-576)300548842  |4 aut 
700 1 |a Wichelhaus, Thomas A.  |e VerfasserIn  |4 aut 
700 1 |8 6\p  |a Hogardt, Michael  |e VerfasserIn  |0 (DE-588)1203232128  |0 (DE-627)168803367X  |4 aut 
700 1 |8 7\p  |a Serr, Annerose  |e VerfasserIn  |0 (DE-588)1136875131  |0 (DE-627)893666297  |0 (DE-576)490897509  |4 aut 
700 1 |8 8\p  |a Hess, Christina  |d 1979-  |e VerfasserIn  |0 (DE-588)1149092009  |0 (DE-627)1009387316  |0 (DE-576)496558536  |4 aut 
700 1 |8 9\p  |a Wendel, Andreas Friedrich  |d 1981-  |e VerfasserIn  |0 (DE-588)139821104  |0 (DE-627)613788192  |0 (DE-576)313414556  |4 aut 
700 1 |a Siegel, Ekkehard  |e VerfasserIn  |4 aut 
700 1 |a Rohde, Holger  |d 1971-  |e VerfasserIn  |0 (DE-588)12361144X  |0 (DE-627)706367197  |0 (DE-576)293789878  |4 aut 
700 1 |a Zimmermann, Stefan  |d 1968-  |e VerfasserIn  |0 (DE-588)129100846  |0 (DE-627)389531790  |0 (DE-576)297493612  |4 aut 
700 1 |8 10\p  |a Steinmann, Jörg Helmut  |d 1978-  |e VerfasserIn  |0 (DE-588)134133048  |0 (DE-627)561350337  |0 (DE-576)300332483  |4 aut 
773 0 8 |i Enthalten in  |t Antibiotics  |d Basel : MDPI, 2012  |g 11(2022), 5, Artikel-ID 545, Seite 1-6  |h Online-Ressource  |w (DE-627)726120596  |w (DE-600)2681345-2  |w (DE-576)371374081  |x 2079-6382  |7 nnas  |a German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assay 
773 1 8 |g volume:11  |g year:2022  |g number:5  |g month:sp  |g elocationid:545  |g pages:1-6  |g extent:6  |a German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assay 
856 4 0 |u https://doi.org/10.3390/antibiotics11050545  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2079-6382/11/5/545  |x Verlag  |z lizenzpflichtig  |3 Volltext 
883 |8 1\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 2\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 3\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 4\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 5\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 6\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 7\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 8\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 9\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 10\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
951 |a AR 
992 |a 20220727 
993 |a Article 
994 |a 2022 
998 |g 129100846  |a Zimmermann, Stefan  |m 129100846:Zimmermann, Stefan  |d 910000  |d 911700  |e 910000PZ129100846  |e 911700PZ129100846  |k 0/910000/  |k 1/910000/911700/  |p 18 
999 |a KXP-PPN1811789064  |e 4173077823 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1811789064","id":{"doi":["10.3390/antibiotics11050545"],"eki":["1811789064"]},"relHost":[{"title":[{"subtitle":"open access journal","title_sort":"Antibiotics","title":"Antibiotics"}],"pubHistory":["1.2012 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"2012-","publisher":"MDPI","publisherPlace":"Basel","dateIssuedKey":"2012"}],"note":["Gesehen am 12.09.12"],"recId":"726120596","id":{"eki":["726120596"],"zdb":["2681345-2"],"issn":["2079-6382"]},"disp":"German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assayAntibiotics","physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"11(2022), 5, Artikel-ID 545, Seite 1-6","issue":"5","year":"2022","extent":"6","pages":"1-6","volume":"11"},"language":["eng"]}],"name":{"displayForm":["Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann and Jörg Steinmann"]},"physDesc":[{"extent":"6 S."}],"language":["eng"],"person":[{"role":"aut","given":"Jana","family":"Manzke","display":"Manzke, Jana"},{"display":"Stauf, Raphael","family":"Stauf","given":"Raphael","role":"aut"},{"display":"Neumann, Bernd","given":"Bernd","family":"Neumann","role":"aut"},{"family":"Molitor","given":"Ernst","display":"Molitor, Ernst","role":"aut"},{"role":"aut","display":"Hischebeth, Gunnar","family":"Hischebeth","given":"Gunnar"},{"family":"Simon","given":"Michaela","display":"Simon, Michaela","role":"aut"},{"role":"aut","given":"Jonathan","family":"Jantsch","display":"Jantsch, Jonathan"},{"role":"aut","display":"Rödel, Jürgen","family":"Rödel","given":"Jürgen"},{"family":"Becker","given":"Sören Leif","display":"Becker, Sören Leif","role":"aut"},{"role":"aut","given":"Alexander","family":"Halfmann","display":"Halfmann, Alexander"},{"given":"Thomas A.","family":"Wichelhaus","display":"Wichelhaus, Thomas A.","role":"aut"},{"role":"aut","display":"Hogardt, Michael","given":"Michael","family":"Hogardt"},{"given":"Annerose","family":"Serr","display":"Serr, Annerose","role":"aut"},{"role":"aut","given":"Christina","family":"Hess","display":"Hess, Christina"},{"role":"aut","display":"Wendel, Andreas Friedrich","given":"Andreas Friedrich","family":"Wendel"},{"family":"Siegel","given":"Ekkehard","display":"Siegel, Ekkehard","role":"aut"},{"role":"aut","family":"Rohde","given":"Holger","display":"Rohde, Holger"},{"display":"Zimmermann, Stefan","given":"Stefan","family":"Zimmermann","role":"aut"},{"role":"aut","family":"Steinmann","given":"Jörg Helmut","display":"Steinmann, Jörg Helmut"}],"title":[{"title_sort":"German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assay","title":"German multicenter study analyzing antimicrobial activity of ceftazidime-avibactam of clinical meropenem-resistant pseudomonas aeruginosa isolates using a commercially available broth microdilution assay"}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"19 April 2022"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["This article belongs to the special issue \"Carbapenem-Resistant Organisms (CRO) as leading cause of hospital associated infections\"","Gesehen am 27.07.2022"]} 
SRT |a MANZKEJANAGERMANMULT1920